Capital Research Global Investors Inhibrx, Inc. Transaction History

Capital Research Global Investors

  • $463 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
SELL
$14.5 - $38.0 $7.39 Million - $19.4 Million
-509,361 Reduced 41.69%
712,360 $27.1 Million
Q3 2023

Nov 13, 2023
SELL
$15.75 - $26.31 $8.35 Million - $13.9 Million
-530,192 Reduced 30.26%
1,221,721 $22.4 Million
Q1 2023

May 15, 2023
BUY
$18.45 - $27.14 $32.3 Million - $47.5 Million
1,751,913 New
1,751,913 $33.1 Million

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Capital Research Global Investors Portfolio

Follow Capital Research Global Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital Research Global Investors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email